Outlook Therapeutics, Inc.
OTLK
$0.39
$0.039.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -119.74% | 17.17% | 53.81% | 113.27% | 9.10% |
| Total Depreciation and Amortization | 3.32% | 2.72% | 20.56% | 46.45% | 85.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 277.15% | -57.11% | -153.03% | -184.38% | -374.47% |
| Change in Net Operating Assets | -135.22% | 312.52% | 179.90% | 179.06% | 236.64% |
| Cash from Operations | 16.38% | 24.66% | 12.58% | -9.94% | -41.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3,285,590.91% | -840,425.58% | -456,886.49% | -316,342.31% | 90.98% |
| Issuance of Common Stock | -0.60% | -20.55% | -45.70% | -60.73% | 986.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | 66.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.31% | -25.43% | -47.02% | -60.60% | 1,112.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 163.92% | 19.14% | -1,272.56% | -1,202.02% | 88.91% |